Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Nitec Pharma AG |
---|---|
Information provided by: | Nitec Pharma AG |
ClinicalTrials.gov Identifier: | NCT00650078 |
The purpose of the study is to compare the safety and efficacy, with regards to the signs and symptoms, of MR prednisone (Lodotra®) versus placebo in combination with standard Disease Modifying Anti-Rheumatic Drug (DMARD) treatment in patients with active rheumatoid arthritis.
Condition | Intervention | Phase |
---|---|---|
Rheumatoid Arthritis |
Drug: MR tablet formulation of prednisone Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized Multi-Center, Double-Blind, Placebo-Controlled Study of a New Modified-Release Tablet Formulation of Prednisone (Lodotra®) in Patients With Rheumatoid Arthritis |
Estimated Enrollment: | 294 |
Study Start Date: | March 2008 |
Study Completion Date: | July 2009 |
Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental |
Drug: MR tablet formulation of prednisone
1 x 5 mg daily
|
B: Placebo Comparator |
Drug: Placebo
1x daily
|
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Use of glucocorticoids:
Principal Investigator: | Frank Buttgereit, Prof. Dr. | Charité Campus Mitte, Germany |
Responsible Party: | Nitec Pharma GmbH ( Chief Medical Officer ) |
Study ID Numbers: | NP01-007, EudraCT-Number: 2007-003508-36 |
Study First Received: | March 28, 2008 |
Last Updated: | July 17, 2009 |
ClinicalTrials.gov Identifier: | NCT00650078 History of Changes |
Health Authority: | United States: Food and Drug Administration; Germany: Ethics Commission; Germany: Federal Institute for Drugs and Medical Devices; Hungary: National Institute of Pharmacy; Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products; United Kingdom: Medicines and Healthcare Products Regulatory Agency; United Kingdom: Research Ethics Committee; Canada: Health Canada |
Signs and Symptoms Autoimmune Diseases Joint Diseases Arthritis |
Connective Tissue Diseases Arthritis, Rheumatoid Rheumatic Diseases Predniso(lo)ne |
Anti-Inflammatory Agents Prednisone Autoimmune Diseases Antineoplastic Agents, Hormonal Joint Diseases Hormone Antagonists Arthritis, Rheumatoid Hormones, Hormone Substitutes, and Hormone Antagonists |
Rheumatic Diseases Glucocorticoids Hormones Signs and Symptoms Musculoskeletal Diseases Arthritis Connective Tissue Diseases |
Anti-Inflammatory Agents Prednisone Autoimmune Diseases Antineoplastic Agents, Hormonal Immune System Diseases Antineoplastic Agents Joint Diseases Physiological Effects of Drugs Arthritis, Rheumatoid |
Hormones, Hormone Substitutes, and Hormone Antagonists Rheumatic Diseases Glucocorticoids Hormones Pharmacologic Actions Musculoskeletal Diseases Therapeutic Uses Arthritis Connective Tissue Diseases |